Analysis and Insights
Valuation Metrics:
Dillard's (DDS) current valuation metrics suggest a mixed outlook. The price-to-earnings (P/E) ratio for Q3 2025 is 9.02, rising to 12.52 in Q4, indicating moderate valuation relative to earnings. The EV/EBITDA ratio is 5.37 for Q3 and 7.62 for Q4, signaling reasonable valuation compared to earnings before interest, taxes, depreciation, and amortization. The price-to-sales (P/S) ratio is 0.85 for Q3 and 1.13 for Q4, which is relatively low, suggesting undervaluation. However, the price-to-book (P/B) ratio is 2.83 for Q3 and 4.09 for Q4, indicating a premium relative to book value.
Financial Performance:
Dillard's financial performance shows stability with total revenue of $1.45 billion for both Q3 and Q4 2025. Net income increased significantly from $124.596 million in Q3 to $214.4 million in Q4. Gross profit also rose from $587.802 million to $698.2 million, reflecting improved profitability. The return on equity (ROE) is 7.73% for Q3 and 13.48% for Q4, indicating decent returns for shareholders.
Market Sentiment and Analyst Ratings:
The stock's price is $374.98 as of March 25, 2025, with a 52-week range of $328 to $510. The Relative Strength Index (RSI) of 29.1 indicates oversold conditions, suggesting potential buying opportunities. Analyst ratings are mixed, with UBS maintaining a Strong Sell rating and a low price target, while Telsey Advisory Group has a Hold rating with a higher target.
Conclusion:
Based on the analysis, Dillard's (DDS) does not appear to be overvalued. The low P/S ratio and oversold RSI suggest potential undervaluation. However, the high P/B ratio and mixed analyst sentiment warrant caution. Investors should monitor the retail sector's health and company-specific developments.